Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Volunteers Clear all
Completed No phase listed Observational Accepts healthy volunteers

Safety of Three Formulations of Ketasyn Administered for 14 Days in Healthy Elderly

NCT00660088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Ketasyn
Other
Lead sponsor
Cerecin
Industry
Eligibility
55 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2008 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers

NCT04672083
View directory record Official record
Conditions
HIV Infections
Interventions
CPT31, Placebo
Drug
Lead sponsor
Navigen, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

NCT06268860
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab vial injection, Rocatinlimab prefilled syringe
Drug · Combination Product
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 5, 2026, 4:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

NCT06453824
View directory record Official record
Conditions
Safety and Tolerability
Interventions
MDI-2517, Placebo
Drug · Other
Lead sponsor
MDI Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

NCT04571424
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB133 (Dapirolizumab pegol), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

NCT06858696
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Mavorixafor
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Montclair, California • Rialto, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 5, 2026, 4:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of RBI-4000 in Healthy Participants

NCT06048770
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RBI-4000, RabAvert
Biological
Lead sponsor
Replicate Bioscience
Industry
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Miami, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

NCT05391724
View directory record Official record
Conditions
Hepatic Impairment
Interventions
CMX001
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

NCT01064388
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2541546 in Healthy Postmenopausal Women

NCT01742078
View directory record Official record
Conditions
Healthy
Interventions
LY2541546 - IV, LY2541546 - SC, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Evansville, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

NCT01742091
View directory record Official record
Conditions
Healthy
Interventions
LY2541546 - SC, LY2541546 - IV, Placebo - SC, Placebo - IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Daytona Beach, Florida • Honolulu, Hawaii • Evansville, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers

NCT02413255
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-020, TAK-020 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

NCT01751074
View directory record Official record
Conditions
Atherosclerosis
Interventions
Rosuvastatin 10 mg, Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dexpramipexole SAD/MAD Study

NCT01449578
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Dexpramipexole, Dexpramipexole Placebo
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

NCT02160574
View directory record Official record
Conditions
Surgical Site Infection
Interventions
ChloraPrep, 0.1% Sodium Lauryl Sulfate, 0.9% Physiological Saline, ZuraPrep without IPA
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects

NCT06299410
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ITI-1284 10 mg, ITI-1284 20 mg
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 5, 2026, 4:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1, Single and Multiple Doses Study of Sitaxentan in Japanese and Western Subjects

NCT00981968
View directory record Official record
Conditions
Healthy
Interventions
Sitaxentan sodium/Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891
View directory record Official record
Conditions
Healthy
Interventions
VBY-036
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

NCT01014650
View directory record Official record
Conditions
Healthy
Interventions
GLYX-13, IV normal saline
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects

NCT02575482
View directory record Official record
Conditions
Cognitive Disorders
Interventions
SUVN-D4010, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2016 · Synced Oct 5, 2026, 4:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

NCT04187560
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102
Drug
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 5, 2026, 4:39 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 5, 2026, 4:39 AM EDT